Nplate Risk Plan Includes Patient Support Initiatives
This article was originally published in The Pink Sheet Daily
Executive Summary
Prematurely issued press release announcing approval of Amgen chronic ITP therapy provides details on risk evaluation and mitigation strategies.
You may also be interested in...
Amgen’s Nplate Approved With Restricted Access Program
FDA approval of the first platelet producer includes a REMS with a patient and physician tracking program.
Amgen’s Nplate Approved With Restricted Access Program
FDA approval of the first platelet producer includes a REMS with a patient and physician tracking program.
For Amgen’s Nplate, No News Is Good News
FDA tells biotech the agency will miss once-postponed July 23 user fee date.